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Case Reports
Psychogenic Movement Disorders and
Dopamine Transporter Scans: Still
a Clinical Diagnosis?
Guillermo Moguel-Cobos, M.D., Zane Maroney, B.A., Jennifer M. Erickson, D.O.,
Alexander I. Tröster, Ph.D., Davin K. Quinn, M.D.
Introduction
Psychogenic movement disorders (PMDs) are man-
aged ideally via a multidisciplinary approach involv-
ing primary care providers, specialists in neurology,
psychosomatic medicine, physical therapy, and neuro-
psychology, as well as by collaborating with the
patient, family, and acquaintances.1 Obstacles to
efficient therapy include a lack of resources or exper-
tise, differences in the confidence of a PMD diagnosis
between neurologists and psychiatrists, and the stigma
and patient’s response to a PMD diagnosis.
The controversy is ongoing about just how “psycho-
genic” a PMD is, leading to a debate on the best practices
for diagnosis and treatment.2 Functional neuroimaging
studies show abnormal patterns of brain activation
involved in voluntary motor control in patients with
functional paralysis or tremor.3 Various psychoanalytic
explanations of somatization have been published, such as
Winnicott’s4 defensive dissociation, or amore general view
of the mind-body relationship, such asMeissner’s.5 Given
the multiplicity of theoretical models of functional neuro-
logic symptoms and the frequent co-occurrence of psycho-
genic and neurologic disorders,6 ongoing longitudinal
assessment of patients with PMD by both neurologists
and psychiatrists is crucial for appropriate management.
We demonstrate the importance of ongoing
reassessment of PMD through the case of a patient
with fixed dystonia, asthma, and noncardiac chest
pain who was eventually found to have dementia with
Lewy bodies (DLB).
Case Report
Mr.A, a 66-year-oldHispanicmale patient with a history
of anxiety and depression was referred to our movement
disorders clinic in May 2012 for neck dystonia and gait
disorder evaluation. He had been in good health until the
early 2000s when he experienced several health problems,
including insomnia, asthma, acute noncardiac chest pain,
chronic foot and toe pain, and other vague, chronic pains.
His symptoms persisted despite medical treatment by
various clinicians. In 2008, his condition became further
complicatedbysymptomsof severedepressionandanxiety.
Both he and his family had denied cognitive problems. No
primary medical diagnosis had ever been established.
His family believed that his situation was owing to
the lack of a correct diagnosis, the side effects of
medications, and depression. Furthermore, his depres-
sion and anxiety were resistant to psychiatric
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treatment as antidepressants and antipsychotics wors-
ened his condition. Often, attempts by his family to
bring him into the clinic for behavioral health evalua-
tions provoked asthma attacks, and 1 attempt in 2008
led him to jump from a moving vehicle. During his
hospitalization for treatment of that event, a 40-lb
weight loss from anorexia was reported.
His medical history revealed a 3-month period of
symptom remission, with return to work while on
mirtazapine treatment.Unfortunately, he relapsed shortly
thereafter. Over the next 2 years (2010–2012), he had a
gradual onset of neurologic symptoms with generalized
rigidity, gait problems, and slowness. He also had periods
of intermittent remission and exacerbation during this
time. His family reported that he had experienced more
than 10 remissions in a 3-year period. Sudden onset of
lateral neck tilting appeared in 2012.Carbidopa-levodopa
and quetiapine were started for suspected parkinsonism
but caused changes in his personality, hallucinations,
agitation, and violence toward his spouse, prompting
treatment discontinuation. Risperidone was tried briefly
and discontinued because of the recurrence of agitation.
He had no other exposure to dopamine-blocking agents
that could account for his symptoms. All symptoms
except the neck tilt improved after thesemedications were
stopped. He then underwent a dopamine transporter
(DaT) scan to characterize his movement disorder, and
the result was negative.
When he first presented (in 2012) to ourmovement
disorders clinic, his subjective emphasis was on his
neck whereas his family’s emphasis was on his
depressed mood. He had already visited several
neurology centers before presenting to our clinic;
botulinum toxin injections in his neck had been tried
without any benefit. His medical history also included
depression, asthma, gastritis, inguinal hernia repair,
and tonsillectomy. His medications included budeso-
nide inhalation suspension, flunisolide nasal solution,
and alprazolam (0.5-mg half tablet 3 times daily as
needed). His family history was notable in that his
mother had an unspecified psychiatric disorder and his
brother had an obsessive–compulsive disorder.
During his initial examination in our movement
disorders clinic, he was awake, alert, and fully oriented
but with marked mutism and lack of engagement in the
history taking and examination. This behavior was
consistent across several examiners. His examination
also revealed weak and variable effort, slowness, passive
motion resistance without true rigidity, and variability in
movement velocities over time. There was no true
bradykinesia. His neck was fixed in a left laterocollis
posture, with no hypertrophy of the left sternocleido-
mastoid, scalene, levator scapulae, splenius, or trapezius
muscles. There was no volitional effort to bring his head
back to center. Other examination results were within
normal limits. The laboratory assessment results for
metabolic causes were negative. We ruled out inflamma-
tory, infectious, autoimmune, endocrinological, electro-
lyte, and vitamin disorders. Brain and cervical spineMRI
scan results were normal.
A neuropsychological evaluation in August 2012
revealed performance below expectation on tests of
verbal fluency, visuospatial construction, memory, and
attention but with inconsistent responses when presented
with digit strings of similar length, with a suspected
suboptimal effort. The Personality Assessment Inventory
disclosed defensiveness and reluctance to admit minor
faults and elevation in the somatic concern scale. An
electroencephalogram demonstrated a normal posterior
dominant alpha rhythm without slowing, lateralization,
or epileptiform abnormalities. Treatment focused on his
mood, although several psychiatric evaluations were
unsuccessful. The diagnostic workup focused on exclud-
ing the neurologic causes of his clinical presentation.
A second electroencephalogram 3 years later
showed generalized low-voltage slow activity inter-
mixed with symmetric theta and delta waves. During a
subspecialized psychiatric evaluation for psychoso-
matic disorders in May 2015, his speech was notable
for short under-elaborated sentences, intermittent
mutism, and episodes of verbal perseveration. The
Hoffman and grasp reflexes were present bilaterally.
On occasion, he demonstrated visual hallucinations
and sporadic whole-body jerks. Because of neurologic
deficit progression, an 18F-fluorodeoxyglucose-
positron-emission tomography (PET) brain scan was
performed; it showed occipital lobe hypometabolism
consistent with DLB (Figure 1).
Discussion
He was diagnosed with PMD because of symptoms
inconsistent with the organic disease model, recurring
remissions and exacerbations, psychiatric comorbidity,
and negative test results for organic disease, including a
negative DaT scan result. In addition, acute fixed
dystonias are characteristic of PMDs.7,8 Making an
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inclusive diagnosis of PMD is criticized by some, includ-
ing Stone and Edwards, as an “inappropriately narrow
formulation,”2 and the correctness of this approach is still
debated. Physicians could rush to a presumed PMD
diagnosiswhen there is not enough information to achieve
a correct organic diagnosis at a determined time in the
disease course. Schrag et al.7 concluded that fixed
dystonias are almost all psychogenic in nature, whereas
Pringsheim and Lang recommended caution in diagnos-
ingpsychogenicdystonia, given thehistorical biasuntil the
1970s that all dystonias were psychogenic.9 Among
patients with dystonia, the prevalence of PMD ranges
from 20–53%. Neurologists specializing in movement
disorders use the inclusive criteria proposed by Williams
et al. to diagnose psychogenic dystonia.10 These criteria
include inconsistency with classic dystonia symptoms and
the presence of other psychogenic neurologic signs or
symptoms and psychogenic somatic symptoms. Mr. A
can be diagnosedwith clinically established PMDaccord-
ing to theWilliams andFahn criteria.10Moreover, he had
developed symptoms over the course of almost a decade
before we could conclude that his picture was consistent
with DLB.
Our case demonstrates how difficult it may be to
diagnose a neurodegenerative condition such as DLB
in its early stages, especially when the patient does not
present with the core criteria of fluctuating cognitive
impairment, recurrent visual hallucinations, and par-
kinsonism, and when advanced workups return with
negative results. The high baseline intelligence of Mr.
A may have allowed him to camouflage his dementia
during the early stage of the disease, which further
delayed his diagnosis. The coexistence of both disor-
ders is also possible.
Approach to Possible PMD
Key elements in a patient’s history, physical exami-
nation, and therapeutic response may prompt consid-
eration of PMD in the differential diagnosis. Patients
who typically present with PMD have histories that
are inconsistent with organic causes of symptoms.
Miyasaki et al.11 suggested that after ruling out
conditions such as inborn metabolic errors and post-
lesion effects, it is the patient history that should alert
the clinician to evaluate PMD. Clinicians should
consider abrupt onset, static course, spontaneous
remissions, obvious psychiatric disturbance, multiple
somatizations, presence of secondary financial gain,
recent precipitating events, and employment in a
health profession as factors indicative of a potential
PMD diagnosis.11 This last point is noteworthy
because a patient may possess advanced medical
knowledge regarding the disease presentation. Care-
takers of patients may also have medical knowledge
and internalize cardinal features of the disorder.
Spontaneous remission is another principal element
suggestive of psychogenicity, as very few organic
causes demonstrate drastic reductions in physical
findings over short periods of time.
After a review of the patient’s history, a physical
examination should be done. Significant variations in
tremor frequency and rhythmicity were found in 14
patients with psychogenic parkinsonism.9 Various
techniques can delineate a neurologic tremor from a
psychogenic cause. Psychogenic tremors tend to abate
if the patient is distracted while performing an action
(finger to nose). In organic illness, distracting the
patient increases the involuntary movement, although
there are exceptions (tics and tardive akathisia) to this
rule. Another useful approach is having the patient
perform a series of taps at varying frequencies while
observing for entrainment, where the “affected” limb
takes on the frequency manifested in the unaffected
FIGURE 1. 18F-fluorodeoxy glucose-positron-emission tomogra-
phy showing hypometabolism in the occipital lobe. The
darker color density in the frontal lobe indicates
normal glucose metabolism, and in contrast, the
occipital lobe is lighter, indicating hypometabolism.
Used with permission from Barrow Neurological
Institute, Phoenix, Arizona.
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limb. Lastly, a patient’s response to therapeutic
interventions should be monitored.
If the patient’s presentation suggests a parkinso-
nian movement disorder and has elements supporting
both organic and psychogenic causes, then aDaT scan
may be helpful in guiding appropriate interventions by
revealing whether or not the patient is experiencing
actual nigrostriatal degeneration. Figure 2 represents
our approach algorithm for patients suspected of
PMD or parkinsonism.
DaT Scans in Movement Disorders
DaT scans are promising in differentiating the
dopaminergic nigrostriatal neuron loss of Parkinson
disease (PD) from conditions that mimic PD, but they
have intact dopaminergic nigrostriatal regions, such as
essential tremor, drug-induced or vascular parkinson-
ism, and psychogenic parkinsonism.
A DaT scan interpretation requires visual assess-
ment by a trained nuclear medicine radiologist and is
considered a highly reliable diagnostic test.12 A
normal DaT scan result should prompt the provider
to discontinue any inappropriate medications
(e.g., levodopa-carbidopa) and pursue alternate diag-
nostic tests and therapies to address the patient’s
underlying condition. However, drug interactions
must be taken into account for patients being
considered for a DaT as several drugs may interfere
with imaging.13
FIGURE 2. Diagnostic algorithm for patients with suspected PMD. PS¼ parkinsonian syndrome; PD¼Parkinson disease; 18F-FPCIT PET¼
18F-fluorodeoxy glucose-positron-emission tomography; PSP ¼ progressive supranuclear palsy; MSA ¼ multiple system atrophy.
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A small proportion of patients with idiopathic PD
(iPD) may not have presynaptic nigrostriatal degen-
eration and may have a degree of nigrostriatal degen-
eration not detectable with SPECT.12 Although rare,
this should be kept in mind when considering rescan-
ning a patient whomaintains persistent PD symptoms.
In an open-label, single-dose, prospective, clinical
trial of patients with clinically uncertain parkinsonian
syndrome, DaT scanning had a sensitivity of 97% and
specificity of 100% for differentiating PD from essen-
tial tremor.14 The reasons for clinically uncertain PD
included manifesting only 1 of the 3 cardinal signs of
parkinsonism, 2 signs without bradykinesia, poor
response to L-dopa, lack of disease progression, and
atypical signs.1 Patients who underwent DaT scanning
demonstrated a high degree of agreement between the
initial scan and the clinical diagnosis 2 years later on
follow up.15 In a study, DaT scanning increased
clinicians’ confidence in the diagnosis and ultimately
led to a change in the clinical management of 72% of
patients who had positive scan results.14
Imaging Studies and DLB
DLB is the second most common cause of dementia
after Alzheimer disease. AnDLB diagnosis is based on
a clinical assessment and is definitively confirmed by
autopsy studies. McKeith et al.16 proposed diagnostic
criteria for DLB, including the presence of 1 central
criterion (dementia) and 2 core criteria (parkinsonian
symptoms, persistent well-formed visual hallucina-
tions, or fluctuations in cognition). The core clinical
features of DLB reported in the consensus criteria
have a specificity of 80% and a sensitivity of 50%.
Cognitive decline is not noticeable in the beginning
stages of DLB. Thus, it is difficult to make an inclusive
diagnosis of DLB using this criterion; suggestive and
supportive criteria can be helpful.
Tateno et al.17 identified 3 features that, if present,
aid in the diagnosis of possible DLB or disease
suggestive of DLB. These features include rapid eye
movement sleep behavior disorder, severe neuroleptic
sensitivity, and low DaT uptake in the striatum on
SPECT or PET. Of these, Mr. A manifested only
neuroleptic sensitivity. Significant correlations have
been found between decreased striatal DaT levels and
visual hallucinations.18
Our patient also had occipital lobe hypometabo-
lism on PET (Figure 1), a feature noted in the 2005
DLB consensus guidelines.16 Chiba et al.19 reported
that occipital hypometabolism backs a diagnosis of
DLB and perhaps represents the effect of the patho-
physiological process of DLB on rapid eye movement
sleep behavior disorder. Hypometabolism in the
occipital association cortex and primary visual cortex
is also reported to have 90% sensitivity and 80%
specificity for DLB.20
DaT Scans and DLB
Patients with clinical symptoms highly suggestive of
DLB are more likely to have an abnormal DaT scan
result than those with possible DLB, although a
preexisting high index of suspicion of DLB is usually
present before DaT scans are pursued. The clinical
criteria and accuracy of diagnosing DLB vary depend-
ing on the stage of the illness, which is a primary reason
for delaying the referral for an imaging study. Mr. A’s
DaT scan result was normal at the beginning of his
presentation; it would be interesting to know if a
subsequentDaT scan result would have been abnormal.
DaT scanning is reported to have an 87% sensi-
tivity in differentiating DLB vs no DLB, with a
specificity of 94%.21 Others compared imaging results
with neuropathological findings in 22 participants and
found that an abnormal DaT scan result was 78%
sensitive and 90% specific for probable cases of DLB;
no participant with a normal DaT scan result had
DLB at autopsy.22
DaT scansmay provide false-positive diagnoses of
DLB if there is a preexisting vascular lesion in the
corpus striatum. DaT scans correlated only with
motor dysfunction and, to a much lesser degree, with
executive cognitive dysfunction and not with psychi-
atric or overall cognition.23
DaT Scans and Psychogenic Movement Disorders
Given the high sensitivity and specificity of DaT
scans in PD evaluations, clinicians may use this test to
establish the absence of nigrostriatal degeneration in
patients with suspected psychogenic parkinsonism,
once drug-induced and vascular parkinsonism have
been eliminated as the etiology. DaT scans
of 5 patients diagnosed with psychogenic parkinson-
ism, 5 with confirmed iPD, and 5 with healthy controls
showed that 2 of 5 patients with psychogenic parkin-
sonism demonstrated abnormal findings resembling
Moguel-Cobos et al.
Psychosomatics 58:1, January/February 2017 www.psychosomaticsjournal.org 87
those of iPD.24 In 2 of 3 patients with suspected
psychogenic parkinsonism who underwent DaT scan-
ning, severe dopamine transporter abnormalities were
observed, despite there being scarce clinical evidence
of a neurodegenerative etiology.25 In a study of
9 patients with psychogenic parkinsonism monitored
for 2 years after having aDaT scan,26 5 patients whose
evaluations clinically qualified them as having estab-
lished psychogenic parkinsonism had normal DaT
scan results. Of the 4 patients with probable psycho-
genic parkinsonism 3 had normal DaT scan results,
and 1 with abnormal findings was eventually diag-
nosed with iPD. These small studies suggest that DaT
scanning is useful to ensure an organic dopaminergic
deficit is not missed when psychogenicity is suspected.
Although DLB is a diagnostic possibility to explain a
patient’s abnormal movements, as our case demon-
strates, there is a potentially higher risk of false-
negative DaT scan results in these patients.
Conclusions
PMD should be diagnosed with caution, especially
when DLB (or cognitive compromise) is a
consideration or when the patient presents early in
the disease course; the presence of depression in older
adults should suggest a more aggressive inclusive
diagnosis for neurodegenerative conditions. New
imaging modalities such as DaT scans are supportive
of certain diagnoses, such asDLB or iPD, but their use
and interpretationmust always occur in the setting of a
multidisciplinary workup in which longitudinal
(serial) clinical examinations are the mainstay of
diagnosis and treatment.
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